Background: Several guidelines recommend the risk-adapted monitoring of patients with chronic pancreatitis (CP). However, dedicated risk stratification is widely missing in CP. Elderly-CP (disease onset with 60 or more years of age) may represent a subgroup of CP subjects with a distinct course of disease. Aims: We aimed to investigate the clinical presentation of elderly-CP, and if elderly-CP requires an adapted monitoring. Methods: Seven hundred forty one patients with CP were analyzed in a multicenter (Mannheim/Germany, n = 537; Gießen/Germany, n = 100; Donetsk/Ukraine, n = 104), cross-sectional, retrospective study and classified according to the M-ANNHEIM classification. Results: The frequency of elderly-CP was 20% (148/741). In comparison with non-elderly-CP, elderly-CP was less frequently caused by alcohol and nicotine dependency or genetic mutations. In contrast, the frequency of efferent duct abnormalities (p = 0.009, chi-square test) and idiopathic CP (p < 0.0001, chi-square test) increased significantly. The presence of multiple risk factors was found less frequently in elderly-CP than in non-elderly patients (p < 0.0001; chi-square test). Furthermore, elderly-CP was associated with increased rates of pseudocysts (p = 0.0002; chi-square test), endocrine insufficiency (p = 0.001; chi-square test), and the absence of pain (p = 0.04; chi-square test) in the first year of the disease. Conclusion: In elderly-CP, the course of disease significantly differs from non-elderly-CP. Therefore, individualized monitoring strategies for elderly-CP might be necessary.

Journal Section:
Original Paper
Keywords:
Chronic pancreatitis, Elderly, M-ANNHEIM classification, Pain
1.
Majumder S, Chari ST: Chronic pancreatitis. Lancet 2016; 387: 1957–1966.
2.
Szucs A, Marjai T, Szentesi A, Farkas N, Parniczky A, Nagy G, Kui B, Takacs T, Czako L, Szepes Z, Nemeth BC, Vincze A, Par G, Szabo I, Sarlos P, Illes A, Godi S, Izbeki F, Gervain J, Halasz A, Farkas G, Leindler L, Kelemen D, Papp R, Szmola R, Varga M, Hamvas J, Novak J, Bod B, Sahin-Toth M, Hegyi P; Hungarian Pancreatic Study Group: Chronic pancreatitis: multicentre prospective data collection and analysis by the Hungarian pancreatic study group. PLoS One 2017; 12:e0171420.
3.
Forsmark CE: Management of chronic pancreatitis. Gastroenterology 2013; 144: 1282–1291.
4.
Hoffmeister A, Mayerle J, Beglinger C, Buchler MW, Bufler P, Dathe K, Folsch UR, Friess H, Izbicki J, Kahl S, Klar E, Keller J, Knoefel WT, Layer P, Loehr M, Meier R, Riemann JF, Runzi M, Schmid RM, Schreyer A, Tribl B, Werner J, Witt H, Mossner J, Lerch MM; members of the guideline committee: English language version of the S3-consensus guidelines on chronic pancreatitis: Definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol 2015; 53: 1447–1495.
5.
Takacs T, Czako L, Dubravcsik Z, Farkas G, Hegyi P, Hritz I, Kelemen D, Lasztity N, Morvay Z, Olah A, Pap A, Parniczky A, Patai A, Sahin-Toth M, Szentkereszti Z, Szmola R, Tiszlavicz L, Szucs A, Magyar Hasnyalmirigy M: [Chronic pancreatitis. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. Orv Hetil 2015; 156: 262–288.
6.
Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS: Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 2016; 34: 2654–2668.
7.
Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geissler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch M, Lohr M, Luttges J, Lutz M, Mayerle J, Michl P, Moller P, Molls M, Munter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Rocken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E; Guidelines Programme Oncology AWMF; German Cancer Society eV; German Cancer Aid: [S3-guideline exocrine pancreatic cancer]. Z Gastroenterol 2013; 51: 1395–1440.
8.
Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O’Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D: Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 2016; 34: 2784–2796.
9.
Rosendahl J, Witt H, Szmola R, Bhatia E, Ozsvari B, Landt O, Schulz HU, Gress TM, Pfützer R, Löhr M, Kovacs P, Bluher M, Stumvoll M, Choudhuri G, Hegyi P, te Morsche RH, Drenth JP, Truninger K, Macek M Jr, Puhl G, Witt U, Schmidt H, Buning C, Ockenga J, Kage A, Groneberg DA, Nickel R, Berg T, Wiedenmann B, Bodeker H, Keim V, Mössner J, Teich N, Sahin-Toth M: Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet 2008; 40: 78–82.
10.
Rosendahl J, Kirsten H, Hegyi E, Kovacs P, Weiss FU, Laumen H, Lichtner P, Ruffert C, Chen JM, Masson E, Beer S, Zimmer C, Seltsam K, Algul H, Buhler F, Bruno MJ, Bugert P, Burkhardt R, Cavestro GM, Cichoz-Lach H, Farre A, Frank J, Gambaro G, Gimpfl S, Grallert H, Griesmann H, Grutzmann R, Hellerbrand C, Hegyi P, Hollenbach M, Iordache S, Jurkowska G, Keim V, Kiefer F, Krug S, Landt O, Leo MD, Lerch MM, Levy P, Loffler M, Lohr M, Ludwig M, Macek M, Malats N, Malecka-Panas E, Malerba G, Mann K, Mayerle J, Mohr S, Te Morsche RHM, Motyka M, Mueller S, Muller T, Nothen MM, Pedrazzoli S, Pereira SP, Peters A, Pfutzer R, Real FX, Rebours V, Ridinger M, Rietschel M, Rosmann E, Saftoiu A, Schneider A, Schulz HU, Soranzo N, Soyka M, Simon P, Skipworth J, Stickel F, Strauch K, Stumvoll M, Testoni PA, Tonjes A, Werner L, Werner J, Wodarz N, Ziegler M, Masamune A, Mossner J, Ferec C, Michl P, P H Drenth J, Witt H, Scholz M, Sahin-Toth M; all members of the PanEuropean Working group on ACP: Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. Gut 2018; 67: 1855–1863.
11.
Witt H, Beer S, Rosendahl J, Chen JM, Chandak GR, Masamune A, Bence M, Szmola R, Oracz G, Macek M Jr, Bhatia E, Steigenberger S, Lasher D, Buhler F, Delaporte C, Tebbing J, Ludwig M, Pilsak C, Saum K, Bugert P, Masson E, Paliwal S, Bhaskar S, Sobczynska-Tomaszewska A, Bak D, Balascak I, Choudhuri G, Nageshwar Reddy D, Rao GV, Thomas V, Kume K, Nakano E, Kakuta Y, Shimosegawa T, Durko L, Szabo A, Schnur A, Hegyi P, Rakonczay Z Jr, Pfutzer R, Schneider A, Groneberg DA, Braun M, Schmidt H, Witt U, Friess H, Algul H, Landt O, Schuelke M, Kruger R, Wiedenmann B, Schmidt F, Zimmer KP, Kovacs P, Stumvoll M, Bluher M, Muller T, Janecke A, Teich N, Grutzmann R, Schulz HU, Mossner J, Keim V, Lohr M, Ferec C, Sahin-Toth M: Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet 2013; 45: 1216–1220.
12.
Hegyi P, Wilschanski M, Muallem S, Lukacs GL, Sahin-Toth M, Uc A, Gray MA, Rakonczay Z Jr, Maleth J: CFTR: a new horizon in the pathomechanism and treatment of pancreatitis. Rev Physiol Biochem Pharmacol 2016; 170: 37–66.
13.
Keller J, Layer P: Idiopathic chronic pancreatitis. Best Pract Res Clin Gastroenterol 2008; 22: 105–113.
14.
Hegyi E, Sahin-Toth M: Genetic risk in chronic pancreatitis: The Trypsin-Dependent Pathway. Dig Dis Sci 2017; 62: 1692–1701.
15.
Schneider A: Serine protease inhibitor Kazal type 1 mutations and pancreatitis. Gastroenterol Clin North Am 2004; 33: 789–806.
16.
Lin Y, Tamakoshi A, Matsuno S, Takeda K, Hayakawa T, Kitagawa M, Naruse S, Kawamura T, Wakai K, Aoki R, Kojima M, Ohno Y: Nationwide epidemiological survey of chronic pancreatitis in Japan. J Gastroenterol 2000; 35: 136–141.
17.
Schneider A, Löhr JM, Singer MV: The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol 2007; 42: 101–119.
18.
Schneider A, Rosendahl J, Bugert P, Weiss C, Unterschutz H, Kylanpaa-Back ML, Lempinen M, Kemppainen E, Diaconu BL, Ebert MP, Pfutzer RH: Genetic variants in the manganese superoxide dismutase 2 gene and in the catalase gene are not associated with alcoholic chronic pancreatitis. Alcohol Alcohol 2017; 52: 535–541.
19.
Schneider A, Michaely H, Ruckert F, Weiss C, Strobel P, Belle S, Hirth M, Wilhelm TJ, Haas SL, Jesenofsky R, Schonberg S, Marx A, Singer MV, Ebert MP, Pfutzer RH, Lohr JM: Diagnosing autoimmune pancreatitis with the unifying-autoimmune-pancreatitis-criteria. Pancreatology 2017; 17: 381-394.
20.
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Annals of internal medicine 2007; 147: 573–577.
21.
Ammann RW: Chronic pancreatitis in the elderly. Gastroenterol Clin North Am 1990; 19: 905–914.
22.
Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP: The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994; 107: 1481–1487.
23.
Kamisawa T, Yoshiike M, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Nakamura T: Chronic pancreatitis in the elderly in Japan. Pancreatology 2004; 4: 223–227; discussion 227–228.
24.
Lohr JM, Panic N, Vujasinovic M, Verbeke CS: The ageing pancreas: a systematic review of the evidence and analysis of the consequences. J Intern Med 2018; 283: 446–460.
25.
Stamm BH: Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Hum pathol 1984; 15: 677–683.
26.
Aghdassi A, Mayerle J, Kraft M, Sielenkamper AW, Heidecke CD, Lerch MM: Diagnosis and treatment of pancreatic pseudocysts in chronic pancreatitis. Pancreas 2008; 36: 105–112.
27.
Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP: The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994; 107: 1481–1487.
28.
Ito T, Ishiguro H, Ohara H, Kamisawa T, Sakagami J, Sata N, Takeyama Y, Hirota M, Miyakawa H, Igarashi H, Lee L, Fujiyama T, Hijioka M, Ueda K, Tachibana Y, Sogame Y, Yasuda H, Kato R, Kataoka K, Shiratori K, Sugiyama M, Okazaki K, Kawa S, Tando Y, Kinoshita Y, Watanabe M, Shimosegawa T: Evidence-based clinical practice guidelines for chronic pancreatitis 2015. J Gastroenterol 2016; 51: 85–92.
29.
Whitcomb DC, Shimosegawa T, Chari ST, Forsmark CE, Frulloni L, Garg P, Hegyi P, Hirooka Y, Irisawa A, Ishikawa T, Isaji S, Lerch MM, Levy P, Masamune A, Wilcox CM, Windsor J, Yadav D, Sheel A, Neoptolemos JP; Working Group for the International (IAP – APA – JPS – EPC) Consensus Guidelines for Chronic Pancreatitis: International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the international association of pancreatology, American pancreatic association, Japan pancreas society, pancreasFest working group and European pancreatic club. Pancreatology 2018, Epub ahead of print.
30.
Ahmed Ali U, Nieuwenhuijs VB, van Eijck CH, Gooszen HG, van Dam RM, Busch OR, Dijkgraaf MG, Mauritz FA, Jens S, Mast J, van Goor H, Boermeester MA; Dutch Pancreatitis Study Group: Clinical outcome in relation to timing of surgery in chronic pancreatitis: a nomogram to predict pain relief. Arch Surg 2012; 147: 925–932.
© 2019 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2019
You do not currently have access to this content.